John Black Professor of Bionanoscience , University of OxfordKavli Institute for Nanoscience Discovery
Prof Molly Stevens FREng FRS is John Black Professor of Bionanoscience at the University of Oxford and also holds part-time professorships at Imperial College London and the Karolinska Institute. Molly’s multidisciplinary research balances the investigation of fundamental science with the development of technology to address some of the major healthcare challenges. She is a serial entrepreneur and the founder of several companies in the diagnostics, advanced therapeutics and regenerative medicine space. Her work has been instrumental in elucidating the bio-material interfaces. She has created a broad portfolio of designer biomaterials for applications in disease diagnostics and regenerative medicine. Her substantial body of work influences research groups around the world (>430 publications, h-index 104, >44k citations, 2018, 2021 and 2022 Clarivate Analytics Highly Cited Researcher in Cross-Field research).
University Distinguished Professor and Department Chair of Biomedical Engineering, Ole and Marty Jensen Endowed Chair, School of Dentistry, and Distinguished Professor of Molecular Pharmaceutics, The University of Utah
David W. Grainger is a University Distinguished Professor and Department Chair of Biomedical Engineering, and Distinguished Professor of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, USA. Grainger’s research focuses on improving cell regenerative therapy through allogenic approaches, implanted medical device and clinical diagnostics performance, and nanomaterials toxicity. His research awards include the 2020 International Award from the European Society for Biomaterials, a 2016 Fulbright Scholar Award (New Zealand), the 2013 Excellence in Surface Science Award (Surfaces in Biomaterials Foundation), the 2007 Clemson Award for Basic Research (Society for Biomaterials), the 2005 American Pharmaceutical Research and Manufacturer’s Association’s “Excellence in Pharmaceutics” award, and 2019 Daniels Fund Award for Education in Research Ethics. Grainger emphasizes translational approaches to clinical biomaterials, and validation of clinical effectiveness in implants and drug delivery systems for value-based medicine.
Washington Research Foundation Professor of Bioengineering and Director for the Molecular Engineering and Sciences Institute, University of Washington
Suzie H. Pun is the Washington Research Foundation Professor of Bioengineering and Director for the Molecular Engineering and Sciences Institute at University of Washington. She is a fellow of the U.S. National Academy of Inventors (NAI) has been recognized with the Presidential Early Career Award for Scientists and Engineers and the University of Washington’s Marsha Landolt Distinguished Graduate Mentor Award for her dedicated mentoring of students. She currently serves as an Associate Editor for ACS Biomaterials Science and Engineering. Suzie Pun received her B.S. from Stanford University and her Ph.D. from the California Institute of Technology in Chemical Engineering.
Associate Professor, Electronic Components, Technology and Materials
Delft University of Technology
Massimo Mastrangeli is Associate Professor in the Electronic Components, Technology and Materials (ECTM) group of the Microelectronics department of Delft University of Technology (Delft, NL), where he is developing innovative microelectromechanical organ-on-chip devices and platforms. He got his BSc and MSc degrees cum laude in Electronic Engineering from University of Pisa (IT), and his PhD degree in Materials Engineering from University of Leuven (BE). He held research positions at École Polytechnique Fédérale de Lausanne (EPFL, CH), Université Libre de Bruxelles (BE) and Max Planck Institute for Intelligent Systems (Stuttgart, DE). Massimo is also Guest Lecturer at EPFL and Board Member of the European Organ-on-Chip Society (EUROoCS).
Full Professor, Pharmacology, University of Geneva
Carole Bourquin is full professor of Pharmacology at the University of Geneva. She heads the group of Immunopharmacology of Cancer at the Institute of Pharmaceutical Sciences of Western Switzerland. Her research focuses on uncovering mechanisms that control immune activation in cancer, in order to improve the efficacy of cancer immunotherapy in patients. Prof. Bourquin addresses these questions using translational approaches that range from preclinical cancer models to patient-oriented research. An important aspect of her work is the use of nanodelivery systems to target immunomodulatory drugs to their site of action. Prof. Bourquin is also a practicing clinical pharmacologist at the Geneva University Hospital.